A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
Stopped Terminated early for lack of efficacy as determined by interim endpoint analyses
Conditions
Interventions
- DRUG: LJPC-401
- DRUG: LJPC-401
Sponsor
La Jolla Pharmaceutical Company